Literature DB >> 2260621

Myogenic regulatory protein (MyoD1) expression in childhood solid tumors: diagnostic utility in rhabdomyosarcoma.

P Dias1, D M Parham, D N Shapiro, B L Webber, P J Houghton.   

Abstract

Transcripts for the muscle regulatory gene MyoD1 are expressed during normal skeletal muscle myogenesis and in rhabdomyosarcomas but not in other tissues or in soft-tissue sarcomas. Here we report the distribution of MyoD1 protein, determined by reactivity with anti-MyoD1 polyclonal sera in normal tissues, rhabdomyosarcoma cell lines, and in a variety of pediatric solid tumors. The distribution of MyoD1 protein was highly restricted in normal tissues and was detected only in fetal skeletal muscle and more faintly in adult skeletal muscle. All six human rhabdomyosarcoma cell lines analyzed expressed MyoD1 mRNA transcripts as well as immunoreactive protein. The immunohistochemical expression of MyoD1 protein was then examined in 49 surgical specimens from a variety of pediatric solid tumors. Each of 16 rhabdomyosarcoma specimens was positive for MyoD1, including four that did not express the intermediate filament protein desmin. Two of five specimens originally designated sarcoma type indeterminate (STI) and two of three specimens originally designated extraosseous Ewing's sarcoma (EOE) were positive for MyoD1, suggesting commitment to myogenic differentiation. Three of eight Wilms' tumors, which also expressed desmin and had clearly evident myogenic elements, also were positive for MyoD1. Tumors that failed to express MyoD1 protein included neuroblastoma, primitive neuroectodermal tumor, non-Hodgkins lymphoma, embryonal sarcoma of the liver, malignant fibrous histiocytoma, malignant rhabdoid tumor, and Ewing's sarcoma of the bone. These results indicate that expression of MyoD1 protein is highly restricted in normal human tissues and that expression of this gene product in malignant tissue may be diagnostic for rhabdomyosarcoma. Furthermore MyoD1 staining may be a valuable adjunct in the classification of pediatric soft-tissue sarcomas.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2260621      PMCID: PMC1877713     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  32 in total

1.  Diagnosis of rhabdomyosarcomas with HHF35, a monoclonal antibody directed against muscle actins.

Authors:  R A Schmidt; R Cone; J E Haas; A M Gown
Journal:  Am J Pathol       Date:  1988-04       Impact factor: 4.307

2.  Malignant rhabdoid tumor of the kidney and soft tissues. Evidence for a diverse morphological and immunocytochemical phenotype.

Authors:  M Tsokos; G Kouraklis; R S Chandra; B S Bhagavan; T J Triche
Journal:  Arch Pathol Lab Med       Date:  1989-02       Impact factor: 5.534

3.  Interactions between heterologous helix-loop-helix proteins generate complexes that bind specifically to a common DNA sequence.

Authors:  C Murre; P S McCaw; H Vaessin; M Caudy; L Y Jan; Y N Jan; C V Cabrera; J N Buskin; S D Hauschka; A B Lassar
Journal:  Cell       Date:  1989-08-11       Impact factor: 41.582

4.  Activation of muscle-specific genes in pigment, nerve, fat, liver, and fibroblast cell lines by forced expression of MyoD.

Authors:  H Weintraub; S J Tapscott; R L Davis; M J Thayer; M A Adam; A B Lassar; A D Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

5.  MyoD1: a nuclear phosphoprotein requiring a Myc homology region to convert fibroblasts to myoblasts.

Authors:  S J Tapscott; R L Davis; M J Thayer; P F Cheng; H Weintraub; A B Lassar
Journal:  Science       Date:  1988-10-21       Impact factor: 47.728

6.  Histopathology of childhood sarcomas, Intergroup Rhabdomyosarcoma Studies I and II: clinicopathologic correlation.

Authors:  W A Newton; E H Soule; A B Hamoudi; H M Reiman; H Shimada; M Beltangady; H Maurer
Journal:  J Clin Oncol       Date:  1988-01       Impact factor: 44.544

7.  Immunohistologic studies of tumors containing myosin.

Authors:  W Johnson; J Jurand; R Hiramoto
Journal:  Am J Pathol       Date:  1965-12       Impact factor: 4.307

8.  Expression of intermediate filaments in malignant fibrous histiocytomas.

Authors:  T Hirose; E Kudo; T Hasegawa; J Abe; K Hizawa
Journal:  Hum Pathol       Date:  1989-09       Impact factor: 3.466

9.  Myofibroblasts from diverse pathologic settings are heterogeneous in their content of actin isoforms and intermediate filament proteins.

Authors:  O Skalli; W Schürch; T Seemayer; R Lagacé; D Montandon; B Pittet; G Gabbiani
Journal:  Lab Invest       Date:  1989-02       Impact factor: 5.662

10.  Rhabdomyosarcoma in childhood. An immunohistological analysis with myoglobin, desmin and vimentin.

Authors:  R Kodet
Journal:  Pathol Res Pract       Date:  1989-08       Impact factor: 3.250

View more
  22 in total

1.  A comparison of MyoD1 and fetal acetylcholine receptor expression in childhood tumors and normal tissues: implications for the molecular diagnosis of minimal disease in rhabdomyosarcomas.

Authors:  S Gattenloehner; B Dockhorn-Dworniczak; I Leuschner; A Vincent; H K Müller-Hermelink; A Marx
Journal:  J Mol Diagn       Date:  1999-11       Impact factor: 5.568

2.  Bipolar (neural and myoblastic) phenotype in cell lines derived from human germ cell tumours of testis.

Authors:  S Navarro; R Noguera; A Peydró-Olaya; A Llombart-Bosch
Journal:  Virchows Arch       Date:  1997-04       Impact factor: 4.064

3.  A point mutation in the MyoD basic domain imparts c-Myc-like properties.

Authors:  M E Van Antwerp; D G Chen; C Chang; E V Prochownik
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

Review 4.  MyoD and the regulation of myogenesis by helix-loop-helix proteins.

Authors:  S J Tapscott; H Weintraub
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

5.  The fetal form of the acetylcholine receptor distinguishes rhabdomyosarcomas from other childhood tumors.

Authors:  S Gattenloehner; A Vincent; I Leuschner; S Tzartos; H K Müller-Hermelink; T Kirchner; A Marx
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

6.  Detection of the MyoD1 transcript in rhabdomyosarcoma cell lines and tumor samples by reverse transcription polymerase chain reaction.

Authors:  E Frascella; A Rosolen
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

7.  Strong immunostaining for myogenin in rhabdomyosarcoma is significantly associated with tumors of the alveolar subclass.

Authors:  P Dias; B Chen; B Dilday; H Palmer; H Hosoi; S Singh; C Wu; X Li; J Thompson; D Parham; S Qualman; P Houghton
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

8.  Methylation alterations of the MyoD1 upstream region are predictive of subclassification of human rhabdomyosarcomas.

Authors:  B Chen; P Dias; J J Jenkins; V H Savell; D M Parham
Journal:  Am J Pathol       Date:  1998-04       Impact factor: 4.307

9.  Myogenic regulatory protein expression in adult soft tissue sarcomas. A sensitive and specific marker of skeletal muscle differentiation.

Authors:  G Tallini; D M Parham; P Dias; C Cordon-Cardo; P J Houghton; J Rosai
Journal:  Am J Pathol       Date:  1994-04       Impact factor: 4.307

10.  Expression of transforming growth factor-beta isoforms in small round cell tumors of childhood. An immunohistochemical study.

Authors:  B K McCune; K Patterson; R S Chandra; S Kapur; M B Sporn; M Tsokos
Journal:  Am J Pathol       Date:  1993-01       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.